Go Deep
Ipca Laboratories Limited
Ipca Laboratories Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,302 | 37.6 | 6.12 | 0.09 | 1,945.00 |
| Oct 2026 | 20,293 | 37.6 | 6.11 | 0.09 | 1,943.20 |
| Oct 2026 | 19,912 | 37.1 | 6.03 | 0.09 | 1,915.40 |
Ipca Laboratories Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 27,881,000,000.0 | 23,884,800,000.0 | 23,925,000,000.0 | 25,565,000,000.0 |
| Net Profit | 4,018,900,000.0 | 2,990,700,000.0 | 3,262,700,000.0 | 2,825,700,000.0 |
| EPS | 15.8 | 11.8 | 12.9 | 11.1 |
Ipca Laboratories Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 95,625,400,000.0 | 88,546,000,000.0 | 76,224,100,000.0 | 62,068,500,000.0 | — |
| Net Profit | 11,411,200,000.0 | 7,376,800,000.0 | 5,473,500,000.0 | 4,713,200,000.0 | — |
| EPS | 45.0 | 29.1 | 21.6 | 18.6 | — |
Ipca Laboratories Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 123,701,900,000.0 | 117,605,500,000.0 | 111,012,800,000.0 | 86,264,300,000.0 | — |
| Total Liabilities | 28,461,300,000.0 | 33,722,800,000.0 | 33,742,800,000.0 | 27,111,100,000.0 | — |
| Total Equity | 80,638,100,000.0 | 69,484,500,000.0 | 63,321,900,000.0 | 58,420,200,000.0 | — |
Owes vs Owns
Ipca Laboratories Limited owed ₹0.23 for every ₹1 it owned in Mar 2026, down from ₹0.31 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.23× | 0.29× | 0.30× | 0.31× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Ipca Laboratories Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 9.7%Receivables 16.3%Inventory 22.1%Fixed assets (tangible) 42.6%Intangible assets 1.6%Long-term investments 1.5%Other assets 6.3%
How it's funded — Mar 2026
Short-term debt 4.8%Long-term debt 0.9%Payables 7.6%Other liabilities 9.7%Shareholders' equity 77.0%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,195.6 | 1,105.0 | 852.4 | 2,179.1 |
| Receivables | 2,014.3 | 1,884.1 | 1,686.5 | 989.0 |
| Inventory | 2,731.0 | 2,560.4 | 2,471.3 | 1,743.4 |
| Fixed assets (tangible) | 5,270.9 | 4,762.6 | 4,696.0 | 2,731.6 |
| Intangible assets | 197.6 | 203.2 | 233.2 | 197.2 |
| Long-term investments | 183.6 | 191.0 | 285.0 | 277.2 |
| Other assets | 777.3 | 1,054.1 | 876.8 | 508.9 |
| Liabilities & equity | ||||
| Short-term debt | 594.8 | 758.5 | 807.1 | 805.8 |
| Long-term debt | 109.1 | 543.2 | 580.4 | 651.8 |
| Payables | 940.3 | 846.2 | 776.1 | 525.1 |
| Other liabilities | 1,201.9 | 1,224.4 | 1,210.7 | 728.5 |
| Shareholders' equity | 9,524.1 | 8,388.3 | 7,727.0 | 5,915.3 |
| Net tangible assets | 7,866.2 | 6,745.2 | 6,099.0 | 5,644.8 |
Ipca Laboratories Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 11,419,700,000.0 | 13,213,200,000.0 | 9,446,500,000.0 | 8,058,100,000.0 | — |
| Investing Activities | -2,467,700,000.0 | -8,695,000,000.0 | -12,917,900,000.0 | -7,250,000,000.0 | — |
| Financing Activities | -7,535,200,000.0 | -2,829,800,000.0 | -5,525,500,000.0 | 5,072,400,000.0 | — |